Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice
Copyright © 2022 Pérez-Belmonte, Sanz-Cánovas, Garcia de Lucas, Ricci, Avilés-Bueno, Cobos-Palacios, Pérez-Velasco, López-Sampalo, Bernal-López, Jansen-Chaparro, Miramontes-González and Gómez-Huelgas..
Background: The impact of glucagon-like peptide-1 receptor agonists on patients with heart failure has not been fully described. Our main objective was to evaluate the safety and clinical and glycemic efficacy of once-weekly semaglutide in obese patients with type 2 diabetes and heart failure.
Methods: In this observational, retrospective, real-world study, we enrolled outpatients with type 2 diabetes, obesity, and heart failure who started semaglutide and were followed-up on at 3, 6, and 12 months.
Results: A total of 136 patients were included. From baseline to 12 months, there was a significant improvement on the Kansas City Cardiomyopathy Questionnaire total symptom score (59.0 ± 24.1 vs 79.9 ± 28.4 points, p<0.01), a reduction in the proportion of patients with New York Heart Association functional class III (40.4% to 16.2%, p<0.01), and a reduction in N-terminal pro-brain natriuretic peptide levels (969.5 ± 653.5 vs 577.4 ± 322.1 pg/mL, p<0.01). Emergency department visits due to heart failure, hospitalizations due to heart failure, and all-cause hospitalizations also declined. Additionally, significant reductions in glycated hemoglobin (-1.4%) and body weight (-12.7 kilograms) were observed as well as a de-intensification of antidiabetic therapy. Moreover, semaglutide was safe and well-tolerated.
Conclusion: In obese patients with type 2 diabetes and heart failure, the use of once-weekly semaglutide was safe and clinically efficacious, improving health and functional status. Nevertheless, more strong evidence on glucagon-like peptide-1 receptor agonists in heart failure is required.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Frontiers in endocrinology - 13(2022) vom: 20., Seite 851035 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pérez-Belmonte, Luis M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
53AXN4NNHX |
|---|
| Anmerkungen: |
Date Completed 12.07.2022 Date Revised 24.07.2022 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fendo.2022.851035 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343341050 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343341050 | ||
| 003 | DE-627 | ||
| 005 | 20231226020226.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fendo.2022.851035 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1144.xml |
| 035 | |a (DE-627)NLM343341050 | ||
| 035 | |a (NLM)35813629 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pérez-Belmonte, Luis M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.07.2022 | ||
| 500 | |a Date Revised 24.07.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Pérez-Belmonte, Sanz-Cánovas, Garcia de Lucas, Ricci, Avilés-Bueno, Cobos-Palacios, Pérez-Velasco, López-Sampalo, Bernal-López, Jansen-Chaparro, Miramontes-González and Gómez-Huelgas. | ||
| 520 | |a Background: The impact of glucagon-like peptide-1 receptor agonists on patients with heart failure has not been fully described. Our main objective was to evaluate the safety and clinical and glycemic efficacy of once-weekly semaglutide in obese patients with type 2 diabetes and heart failure | ||
| 520 | |a Methods: In this observational, retrospective, real-world study, we enrolled outpatients with type 2 diabetes, obesity, and heart failure who started semaglutide and were followed-up on at 3, 6, and 12 months | ||
| 520 | |a Results: A total of 136 patients were included. From baseline to 12 months, there was a significant improvement on the Kansas City Cardiomyopathy Questionnaire total symptom score (59.0 ± 24.1 vs 79.9 ± 28.4 points, p<0.01), a reduction in the proportion of patients with New York Heart Association functional class III (40.4% to 16.2%, p<0.01), and a reduction in N-terminal pro-brain natriuretic peptide levels (969.5 ± 653.5 vs 577.4 ± 322.1 pg/mL, p<0.01). Emergency department visits due to heart failure, hospitalizations due to heart failure, and all-cause hospitalizations also declined. Additionally, significant reductions in glycated hemoglobin (-1.4%) and body weight (-12.7 kilograms) were observed as well as a de-intensification of antidiabetic therapy. Moreover, semaglutide was safe and well-tolerated | ||
| 520 | |a Conclusion: In obese patients with type 2 diabetes and heart failure, the use of once-weekly semaglutide was safe and clinically efficacious, improving health and functional status. Nevertheless, more strong evidence on glucagon-like peptide-1 receptor agonists in heart failure is required | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a health status | |
| 650 | 4 | |a heart failure | |
| 650 | 4 | |a obesity | |
| 650 | 4 | |a semaglutide | |
| 650 | 4 | |a type 2 diabetes | |
| 650 | 7 | |a Glucagon-Like Peptide-1 Receptor |2 NLM | |
| 650 | 7 | |a semaglutide |2 NLM | |
| 650 | 7 | |a 53AXN4NNHX |2 NLM | |
| 650 | 7 | |a Glucagon-Like Peptides |2 NLM | |
| 650 | 7 | |a 62340-29-8 |2 NLM | |
| 700 | 1 | |a Sanz-Cánovas, Jaime |e verfasserin |4 aut | |
| 700 | 1 | |a García de Lucas, María D |e verfasserin |4 aut | |
| 700 | 1 | |a Ricci, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Avilés-Bueno, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Cobos-Palacios, Lidia |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Velasco, Miguel A |e verfasserin |4 aut | |
| 700 | 1 | |a López-Sampalo, Almudena |e verfasserin |4 aut | |
| 700 | 1 | |a Bernal-López, M Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a Jansen-Chaparro, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Miramontes-González, José P |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez-Huelgas, Ricardo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in endocrinology |d 2010 |g 13(2022) vom: 20., Seite 851035 |w (DE-627)NLM208813357 |x 1664-2392 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g day:20 |g pages:851035 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fendo.2022.851035 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |b 20 |h 851035 | ||